{"id":67095,"date":"2026-06-02T14:29:00","date_gmt":"2026-06-02T06:29:00","guid":{"rendered":"https:\/\/flcube.com\/?p=67095"},"modified":"2026-06-02T14:29:01","modified_gmt":"2026-06-02T06:29:01","slug":"alphamab-oncologys-her3xtrop2-bispecific-adc-jskn016-shows-64-5-response-rate-in-triple-negative-breast-cancer-at-asco-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67095","title":{"rendered":"Alphamab Oncology&#8217;s HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Alphamab Oncology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>) presented groundbreaking Phase I clinical data at the <strong>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/strong> for <strong>JSKN016<\/strong>, its novel <strong>HER3\u00d7TROP2 bispecific antibody-drug conjugate (ADC)<\/strong>, demonstrating exceptional efficacy in both <strong>triple-negative breast cancer (TNBC)<\/strong> and <strong>HR+\/HER2\u2212 breast cancer<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-design-amp-dose-optimization\" class=\"wp-block-heading\">Clinical Trial Design &amp; Dose Optimization<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Design<\/strong><\/td><td>Phase I dose-escalation and dose-expansion (JSKN016-101)<\/td><\/tr><tr><td><strong>Dose Levels Tested<\/strong><\/td><td>0.5, 1, 2, 4, 6, and 8 mg\/kg (Q3W schedule)<\/td><\/tr><tr><td><strong>Maximum Tolerated Dose (MTD)<\/strong><\/td><td><strong>Not reached<\/strong> at any dose level<\/td><\/tr><tr><td><strong>Recommended Phase 2 Dose (RP2D)<\/strong><\/td><td><strong>6 mg\/kg Q3W<\/strong> for breast cancer patients<\/td><\/tr><tr><td><strong>Data Cutoff<\/strong><\/td><td>March 17, 2026<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable with manageable toxicity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The study successfully identified the optimal dosing regimen without encountering dose-limiting toxicities, enabling administration at therapeutically effective levels.<\/p>\n\n\n\n<h2 id=\"h-efficacy-results-dual-breast-cancer-indications\" class=\"wp-block-heading\">Efficacy Results \u2013 Dual Breast Cancer Indications<\/h2>\n\n\n\n<h3 id=\"h-triple-negative-breast-cancer-tnbc\" class=\"wp-block-heading\">Triple-Negative Breast Cancer (TNBC)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>31 efficacy-evaluable TNBC patients at RP2D<\/td><\/tr><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td><strong>64.5%<\/strong> (investigator-assessed)<\/td><\/tr><tr><td><strong>Median Progression-Free Survival (mPFS)<\/strong><\/td><td><strong>8.5 months<\/strong><\/td><\/tr><tr><td><strong>Clinical Significance<\/strong><\/td><td>Substantial improvement over standard chemotherapy (typically 10-20% ORR)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-hr-her2-breast-cancer\" class=\"wp-block-heading\">HR+\/HER2\u2212 Breast Cancer<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>29 efficacy-evaluable HR+\/HER2\u2212 patients at RP2D<\/td><\/tr><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td><strong>51.7%<\/strong> (investigator-assessed)<\/td><\/tr><tr><td><strong>Median PFS<\/strong><\/td><td>Not yet mature<\/td><\/tr><tr><td><strong>12-Month PFS Rate<\/strong><\/td><td><strong>61.7%<\/strong><\/td><\/tr><tr><td><strong>Clinical Context<\/strong><\/td><td>Impressive activity in heavily pre-treated population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> HER3\u00d7TROP2 bispecific antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Dual Targeting:<\/strong> Simultaneous engagement of HER3 and TROP2 tumor antigens<\/li>\n\n\n\n<li><strong>Payload Delivery:<\/strong> Enhanced tumor-specific drug delivery through dual-target binding<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class bispecific ADC approach combining two validated breast cancer targets<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Overcomes limitations of monospecific ADCs through improved tumor selectivity and internalization<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>TNBC Treatment Gap<\/strong><\/td><td>Limited effective options; median survival &lt;12 months in metastatic setting<\/td><\/tr><tr><td><strong>HR+\/HER2\u2212 Resistance<\/strong><\/td><td>Significant unmet need after CDK4\/6 inhibitor failure<\/td><\/tr><tr><td><strong>ADC Market Evolution<\/strong><\/td><td>Bispecific ADCs represent next-generation platform beyond monospecific constructs<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>Dual targeting may provide superior efficacy and reduced off-tumor toxicity<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Combined addressable population of ~85,000 patients annually in major markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-development-outlook\" class=\"wp-block-heading\">Strategic Implications &amp; Development Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development Pathway:<\/strong> Exceptional Phase I data supports rapid advancement to Phase II\/III trials<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Potential for breakthrough therapy designation based on unprecedented response rates<\/li>\n\n\n\n<li><strong>Commercial Premium:<\/strong> High efficacy in difficult-to-treat populations supports significant pricing power<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success validates Alphamab&#8217;s bispecific ADC technology for additional pipeline candidates<\/li>\n\n\n\n<li><strong>Global Partnership Potential:<\/strong> Strong ASCO data likely to attract international pharmaceutical partnership interest<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The 64.5% ORR in TNBC represents one of the highest response rates ever reported for this aggressive breast cancer subtype, potentially establishing JSKN016 as a new standard of care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations for JSKN016. Actual results may differ due to risks including clinical trial variability, safety findings, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060200036_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060200036_c.\"><\/object><a id=\"wp-block-file--media-3c578242-9388-436b-ab8d-eba343b9fb0e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060200036_c.pdf\">2026060200036_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060200036_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3c578242-9388-436b-ab8d-eba343b9fb0e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG: 9966) presented groundbreaking Phase I clinical data at the 2026 American Society&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,187,17,854],"class_list":["post-67095","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-alphamab-oncology","tag-clinical-trial-results","tag-hkg-9966"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Oncology&#039;s HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) presented groundbreaking Phase I clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for JSKN016, its novel HER3\u00d7TROP2 bispecific antibody-drug conjugate (ADC), demonstrating exceptional efficacy in both triple-negative breast cancer (TNBC) and HR+\/HER2\u2212 breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67095\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology&#039;s HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) presented groundbreaking Phase I clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for JSKN016, its novel HER3\u00d7TROP2 bispecific antibody-drug conjugate (ADC), demonstrating exceptional efficacy in both triple-negative breast cancer (TNBC) and HR+\/HER2\u2212 breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67095\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T06:29:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-02T06:29:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67095#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67095\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology&#8217;s HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026\",\"datePublished\":\"2026-06-02T06:29:00+00:00\",\"dateModified\":\"2026-06-02T06:29:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67095\"},\"wordCount\":471,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Alphamab Oncology\",\"Clinical trial results\",\"HKG: 9966\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67095#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67095\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67095\",\"name\":\"Alphamab Oncology's HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-02T06:29:00+00:00\",\"dateModified\":\"2026-06-02T06:29:01+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) presented groundbreaking Phase I clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for JSKN016, its novel HER3\u00d7TROP2 bispecific antibody-drug conjugate (ADC), demonstrating exceptional efficacy in both triple-negative breast cancer (TNBC) and HR+\\\/HER2\u2212 breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67095#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67095\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67095#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology&#8217;s HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology's HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) presented groundbreaking Phase I clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for JSKN016, its novel HER3\u00d7TROP2 bispecific antibody-drug conjugate (ADC), demonstrating exceptional efficacy in both triple-negative breast cancer (TNBC) and HR+\/HER2\u2212 breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67095","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology's HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026","og_description":"Alphamab Oncology (HKG: 9966) presented groundbreaking Phase I clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for JSKN016, its novel HER3\u00d7TROP2 bispecific antibody-drug conjugate (ADC), demonstrating exceptional efficacy in both triple-negative breast cancer (TNBC) and HR+\/HER2\u2212 breast cancer.","og_url":"https:\/\/flcube.com\/?p=67095","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T06:29:00+00:00","article_modified_time":"2026-06-02T06:29:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67095#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67095"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology&#8217;s HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026","datePublished":"2026-06-02T06:29:00+00:00","dateModified":"2026-06-02T06:29:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67095"},"wordCount":471,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Alphamab Oncology","Clinical trial results","HKG: 9966"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67095#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67095","url":"https:\/\/flcube.com\/?p=67095","name":"Alphamab Oncology's HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-02T06:29:00+00:00","dateModified":"2026-06-02T06:29:01+00:00","description":"Alphamab Oncology (HKG: 9966) presented groundbreaking Phase I clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for JSKN016, its novel HER3\u00d7TROP2 bispecific antibody-drug conjugate (ADC), demonstrating exceptional efficacy in both triple-negative breast cancer (TNBC) and HR+\/HER2\u2212 breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67095#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67095"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67095#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology&#8217;s HER3\u00d7TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67095"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67095\/revisions"}],"predecessor-version":[{"id":67097,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67095\/revisions\/67097"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}